Antipsychotic efficacy measured by real-world observational study

telescope-1082091_640

Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.

[read the full story...]

Depot antipsychotics: If you pay me, you can keep injecting me

15957442702_af350ecae9_k

John Baker looks at the 2-year follow-up results of a cluster RCT on the effectiveness of financial incentives to improve adherence to maintenance treatment with depot antipsychotics.

[read the full story...]

Bipolar disorder in older men linked to increased risk of dementia

15596232627_88e725fe30_k

Elena Marcus presents a recent study that shows how older Australian men with bipolar disorder have an increased risk of dementia and early death.

[read the full story...]

The side-effects of antipsychotics: let’s systematically assess, discuss and act! #NPNR2016

w6txmc29-1358999171

A live blog published at the 22nd International Network for Psychiatric Nursing Research conference in Nottingham.

Written by John Baker, Lucy Brazener, Wendy Cross, Vanessa Garrity, Andrew Grundy, Cher Hallett, Ben Hannigan, Elaine Hanzak and Alan Simpson.

[read the full story...]

It’s a jungle out there: the natural history of behavioural and psychological symptoms of dementia

25092200685_d42e256650_k

Caroline Struthers scrutinises a systematic review on the longitudinal course of behavioural and psychological symptoms of dementia.

[read the full story...]

Schizophrenia, antipsychotics and quality of life: measuring the important things

photo-1436124396594-54d90bf69c66

Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.

[read the full story...]

Adding antidepressants to antipsychotics in schizophrenia: do they work, for what, and are they safe?

7687091514_3bffb55cb0_k

Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and schizophrenia-like psychosis.

[read the full story...]

ITI-007 for schizophrenia

9243814710_c193bba8da_k

Murtada Alsaif summarises a recent 4-week long phase II randomised controlled trial of ITI-007 for the treatment of schizophrenia, which contains some positive results for this novel intervention.

[read the full story...]

Evidence-based guidelines for treating bipolar disorder

2704560472_63b23c8c4e_b

Joseph Hayes summarises the recent British Association for Psychopharmacology guidelines for the treatment of bipolar disorder, and compares their recommendations with those found in the NICE bipolar disorder guidance from 2014.

[read the full story...]

Trends in antipsychotic prescribing in autism

8098699800_489cd3ac5c_k

Angela Hassiotis and James Dove summarise a recent meta-analysis of antipsychotic prescribing and use trends in US youth with autism spectrum disorder and/or learning disabilities.

[read the full story...]